Drug manufacturers should disregard profit and instil security seals on products to help patients identify fakes--this is the message from head of Nigeria's Onitsha Patent and Proprietary Medicine Dealers Union, ahead of a meeting on the topic.
After months of flip-flopping, EU Ministers have today shamefully voted to extend the tariffs of up to 16.5 per cent imposed upon Chinese and Vietnamese shoe imports since 2006. The decision condemns cash-strapped European consumers and struggling retailers to higher footwear prices for a further 15 months.
David Pilling’s article in today’s FT offers an insightful analysis on the benefits for African of Chinese investment. He reveals how China treats Africa as any other business partner- where there is mutual benefit they trade, where there isn’t they don’t.
An article in China View today demonstrates the very real danger of rising green protectionism. Proposals to introduce carbon taxes and impose tariffs upon imports from developing countries, which do not cap their carbon emissions, will hurt developing countries trying to trade their way out of poverty.
FT Energy Source asks: What do you think the impact will be of US President Barack Obama’s decision to attend the summit at the end of the conference rather than the early stages?
Apparently, cement prices in East Africa “need” to be kept artificially high to “protect” cement manufacturers in the East African Community from cheaper imports, or so say the East African Business Council (EABC).
More developments in the Argentinian fake medicines scandal which, in case you haven't been reading, has been linked to key supporters of the President.
Indian industry website Pharmabiz today reports that "health ministry sources" are accusing IPN of "unscientifically" constructing reports on fake medicines--while promoting a new government survey that claims just 0.04% of Indian drugs are fakes.
Let us examine the accusations, whoever they come from:
Britain's state-run National Health Service (NHS) doesn't fare too well in comparisons of cancer survival rates. Every year studies show far more deaths under the NHS's watch than in countries of comparable wealth. "20% higher than Europe" reported a recent headline, while new cancer drugs continue to be rationed, often considered "not cost effective".